• Roberto Bellucci, Edwin P Alyea, Sabina Chiaretti, Catherine J Wu, Emmanuel Zorn, Edie Weller, Bingyan Wu, Christine Canning, Robert Schlossman, Nikhil C Munshi, Kenneth C Anderson, and Jerome Ritz.
• Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney St, M530, Boston, MA 02115, USA.
• Blood. 2005 May 15; 105 (10): 3945-50.

AbstractDonor lymphocyte infusions (DLIs) induce effective graft-versus-tumor responses in patients with multiple myeloma who relapse after allogeneic hematopoietic stem-cell transplantation. The graft-versus-myeloma response is presumably mediated primarily by donor T cells, but recent studies have also demonstrated the presence of antibodies specific for a variety of myeloma-associated antigens in patients who achieve complete remission after DLI. One of the B-cell antigens identified in these studies was B-cell maturation antigen (BCMA), a transmembrane receptor of the tumor necrosis factor (TNF) superfamily that is selectively expressed by mature B cells. The present studies were undertaken to characterize the functional significance of antibodies to BCMA in vivo. Using transfected cells expressing BCMA, antibodies in patient serum were found to react with the cell-surface domain of BCMA. Post-DLI patient serum was able to induce complement-mediated lysis and antibody-dependent cellular cytotoxicity (ADCC) of transfected cells and primary myeloma cells expressing BCMA. BCMA antibodies were only found in post-DLI responders and not in other allogeneic transplant patients or healthy donors. These results demonstrate that BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.

33 keywords...

hide…